Teva Pharmaceutical Industries (TEVA) Upgraded at Goldman Sachs Group

Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by investment analysts at Goldman Sachs Group from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. The firm presently has a $20.00 price target on the stock. Goldman Sachs Group’s price objective suggests a potential upside of 7.47% from the stock’s current price.

TEVA has been the subject of a number of other research reports. TheStreet lowered Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. ValuEngine lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Evercore ISI set a $38.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Thursday, October 26th. Finally, Credit Suisse Group lowered Teva Pharmaceutical Industries from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $25.00 to $13.00 in a research note on Wednesday, August 23rd. Five investment analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average price target of $20.57.

Teva Pharmaceutical Industries (TEVA) traded up $1.31 during trading hours on Friday, hitting $18.61. The stock had a trading volume of 65,928,051 shares, compared to its average volume of 16,294,546. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $38.31. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The stock has a market cap of $15,951.20, a price-to-earnings ratio of 3.63 and a beta of 0.55.

Several large investors have recently made changes to their positions in the stock. Capital Research Global Investors lifted its holdings in shares of Teva Pharmaceutical Industries by 13.8% in the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after acquiring an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. lifted its stake in Teva Pharmaceutical Industries by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after purchasing an additional 6,685,844 shares during the last quarter. FMR LLC lifted its stake in Teva Pharmaceutical Industries by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares during the last quarter. Northern Cross LLC lifted its stake in Teva Pharmaceutical Industries by 14.0% in the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock worth $591,169,000 after purchasing an additional 2,184,172 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in Teva Pharmaceutical Industries by 2.5% in the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock worth $428,033,000 after purchasing an additional 311,894 shares during the last quarter. 52.05% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This report was posted by American Banking and Market News and is owned by of American Banking and Market News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/15/teva-pharmaceutical-industries-teva-upgraded-at-goldman-sachs-group.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)